Fax: (713) 794-4297
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia
Article first published online: 27 JUL 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 19, pages 4533–4539, 1 October 2009
How to Cite
Jain, N., Wierda, W., Ferrajoli, A., Wong, F., Lerner, S., Keating, M. and O'Brien, S. (2009), A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer, 115: 4533–4539. doi: 10.1002/cncr.24522
- Issue published online: 17 SEP 2009
- Article first published online: 27 JUL 2009
- Manuscript Accepted: 11 MAR 2009
- Manuscript Revised: 6 FEB 2009
- Manuscript Received: 21 NOV 2008
- 4Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20: 2453-2463., , , et al.
- 7Iodine I131 tositumomab for patients with small lymphocytic lymphoma (SLL): overall clinical trial experience [abstract]. Blood. 1999; 88. Abstract., , , , , .
- 10Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 2392., , , et al.
- 14Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalln) radiolmmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-Cell non-Hodgkin's lymphoma: results with second-line therapy [abstract]. Blood. 2003; 102: 306b. Abstract 4949., , , et al.